DEA Targets Dentist James Orrington in Drug Order Decision
Published Date: 10/20/2025
Notice
Summary
Dr. James Orrington, a dentist in Chicago, lost his DEA license to handle controlled substances because he no longer has permission to do so in Illinois. He didn’t respond to the government’s attempts to contact him, so the DEA canceled his registration. This means he can’t legally prescribe or manage certain drugs anymore, effective immediately.
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
DEA Registration Revoked for Dentist
The Drug Enforcement Administration revoked James Orrington II's DEA Certificate of Registration No. BO7484811. Because his Illinois dental and controlled-substance licenses were suspended on May 23, 2024, he is not authorized to handle controlled substances in Illinois, and the revocation is effective November 19, 2025.
Pending Registration Applications Denied
The DEA denied any pending applications by James Orrington II to renew or modify his DEA registration and denied any other pending application of his for additional registration in Illinois. Those denials accompany the revocation and are effective November 19, 2025.
State License Required for DEA Registration
The Order reiterates that under federal law (21 U.S.C. 823(g)(1) and 824(a)(3)) a practitioner must be authorized by the State in which they practice to dispense controlled substances in order to hold a DEA registration. If a practitioner's State license is suspended or revoked, the DEA may revoke the federal registration.
15-Day Reconsideration Opportunity
The Order allows James Orrington II to file a properly supported motion for reconsideration of the findings of fact within fifteen calendar days of the date of the Order. Any such motion and responses must be filed and served by email to the other party and to the DEA Office of the Administrator at [email protected].
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-19596 — United States Department of Transportation Advisory Board; Public Meeting
Heads up! The Department of Transportation canceled the Advisory Board public meeting that was set for October 22, 2025. This affects anyone planning to join or follow the meeting, but no new dates or costs were announced yet. Stay tuned for updates so you don’t miss out on future DOT news and decisions!
Next: 2025-19598 — Abolghasem Rezaei, M.D.; Decision and Order
Dr. Abolghasem Rezaei from Oklahoma lost his DEA registration because he no longer has the state permission to handle controlled substances. Since he didn’t ask for a hearing, the DEA canceled his registration by default, meaning he can’t legally prescribe or manage these drugs anymore. This change is effective immediately and impacts Dr. Rezaei’s ability to work with controlled substances.